by PulmPEEPs
Pulmonary and Critical Care content for learners and practitioners of all levels
Language
🇺🇲
Publishing Since
10/27/2021
Email Addresses
1 available
Phone Numbers
0 available
April 8, 2025
Luke Hedrick and Dave Furfaro discuss the MIST 2 trial evaluating enzymatic therapy for complex pleural infections in this interview
March 4, 2025
<br /> We’re back with our second episode in our guideline initiative, and continuing our review of the Global Initiative for Asthma (GINA) guidelines on asthma. In our first episode of this series, we talked about making the diagnosis of asthma, the importance of appropriate phenotyping, and doing an initial assessment of asthma severity. Today, we’re discussing the initial management of asthma and discussing but pharmacologic and non-pharmacologic treatments. We have a great infographic prepared along with the episode, and a boards-style question for your review.<br /> <br /> <br /> <br /> <br /> <br /> <br /> Meet Our Co-Hosts<br /> <br /> <br /> <br /> Rupali Sood grew up in Las Vegas, Nevada and made her way over to Baltimore for medical school at Johns Hopkins. She then completed her internal medicine residency training at Massachusetts General Hospital before returning back to Johns Hopkins, where she is currently a second year pulmonary and critical care medicine fellow alongside Tom. Rupali’s interests include interstitial lung disease, particularly as related to oncologic drugs. And she also loves bedside medical education.<br /> <br /> <br /> <br /> Tom Di Vitantonio is originally from New Jersey and attended medical school at Rutgers, New Jersey Medical School in Newark. He then completed his internal medicine residency at Weill Cornell, where he also served as a chief resident. He currently is a second year pulmonary and critical care medicine fellow at Johns Hopkins, and he’s passionate about caring for critically ill patients, how we approach the management of pulmonary embolism, and also about medical education of trainees to help them be more confident and patient centered in the care they have going forward.<br /> <br /> <br /> <br /> Key Learning Points<br /> <br /> <br /> <br /> <br /> * Introduction to Asthma Guidelines<br /> <br /> <br /> * The podcast continues a guideline series on asthma, focusing on the Global Initiative for Asthma (GINA) 2024 guidelines.<br /> * Emphasizes practical applications for clinicians managing asthma in different settings.<br /> <br /> <br /> * Importance of Evidence-Based Asthma Management<br /> <br /> <br /> * Asthma treatment must be systematic and personalized, considering recent clinical evidence.<br /> * Previous reliance on short-acting beta agonists (SABAs) as rescue inhalers has shifted towards inhaled corticosteroid (ICS)-containing therapies.<br /> * Over-reliance on SABAs is linked to increased exacerbations, airway inflammation, and poor long-term outcomes.<br /> <br /> <br /> * Stepwise Approach to Asthma Management (GINA 2024)<br /> <br /> <br /> * The Track 1 approach (preferred) centers around ICS-formoterol as both maintenance and reliever therapy (MART).<br /> * Track 2 (alternative approach) includes daily ICS or ICS-LABA with a separate SABA as a reliever.<br /> <br /> Stepwise Therapy<br /> <br /> * Step 1-2 (Mild asthma): Low-dose ICS-formoterol as needed for symptom relief.<br /> * Step 3 (Moderate asthma): Low-dose maintenance ICS-formoterol (MART therapy).<br /> * Step 4 (Persistent symptoms): Medium-dose ICS-formoterol (MART) with additional inhaler adjustments.<br /> * Step 5 (Severe asthma): Consider biologic therapies, phenotyping, and additional controllers.<br /> <br /> <br /> * MART Therapy as a Game-Changer<br /> <br /> <br /> * Maintenance and Reliever Therapy (MART):<br /> <br /> * Uses a single inhaler for both daily maintenance and symptom relief.<br /> * Reduces overuse of SABAs.<br /> * Provides real-time up-titration of ICS during exacerbations.<br /> * Leads to better adherence and control.<br /> <br /> <br /> * Supporting Evidence from Trials:<br /> <br /> * SIGMA 1 & 2, Novel Start, Practical (2018-2019): Showed ICS-formoterol reduces exacerbations and steroid exposure compared to SABAs.<br />
February 25, 2025
Dr. Jon Rosenberg, a neuro intensivist, discusses with the PulmPEEPs host how to safely employ prone positioning for patients with elevated intracranial pressure, offering practical insights and best practices for managing these complex cases.
Critical Care Time Podcast
Adam Thomas & Josh Farkas
Brandon Oto, PA-C, FCCM and Bryan Boling, DNP, ACNP, FCCM
Core IM Team
Scott D. Weingart, MD FCCM
CardioNerds
The Curious Clinicians
The Clinical Problem Solvers
JAMA Network
The Curbsiders Internal Medicine Podcast
American College of Physicians
Core EM
JAMA Network
Eddie and Todd
Dr. Anton Helman
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.